Targeting unmet medical needs

XEPTAGEN SpA is engaged in the discovery and validation of novel molecular markers in order to produce innovative diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the proprietary platform technology Combinatorial Proteomic®, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. Our mission includes creating innovative tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.

Press Releases	Link
•  AIGO results on CEA-IgM presented at 18° FISMAD congress.     •  Serum levels of SCCA-IgM predict the efficacy of HCC treatments.     •  Multicenter prospective study on PSA-IgM to reduce negative prostatic ...     •  CompleXima™ HCC biochip shows high accuracy in detecting HCC in ...     •  EU funding assigned to Prolifica project.